Wink, Logan K. http://orcid.org/0000-0001-5232-3870
Adams, Ryan
Horn, Paul S.
Tessier, Charles R.
Bantel, Andrew P.
Hong, Michael
Shaffer, Rebecca C.
Pedapati, Ernest V.
Erickson, Craig A.
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Randomized Placebo-Controlled Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorder
https://doi.org/10.1007/s10803-018-3562-5
Investigational drugs in early-stage clinical trials for autism spectrum disorder
https://doi.org/10.1080/13543784.2019.1649656
Funding for this research was provided by:
Institutional Clinical and Transnational Science Award (8UL1TR000077-04)
Article History
First Online: 11 April 2018
Compliance with Ethical Standards
:
: The authors declare that they have no interests that compete directly with this work, though LKW, CRT, RSC, EVP, and CAE do receive research support from various sources for other work. LKW’s current and/or past research is supported by the Simons Research Foundation, Autism Speaks, Riovant Sciences Ltd, and Cures Within Reach. Dr. Wink is currently a NICHM-NIMH supported T32 fellow. She is an inventor on intellectual property held by Cincinnati Children’s Hospital Research Foundation for a treatment in autism spectrum disorder. LKW has also served as a past consultant for Otsuka and Ovid. CRT has been a past one-time consultant for Confluence Pharmaceuticals. His current and/or past research has been supported by the National Institute of Mental Health and Indiana University School of Medicine. RCS receives research support from the Rubenstein foundation. EVP receives research support from Cincinnati Children’s Hospital Research Foundation and the National Institutes of Health. CAE has received current and/or past research support from the National Institutes of Health, the United States Department of Defense, the United States Centers for Disease Control, the John Merck Fund, Autism Speaks, the Simons Foundation, Cincinnati Children’s Hospital Research Foundation, the FRAXA Research Foundation, the National Fragile X Foundation, the Roche Group, Seaside Therapeutics, Novartis, Neuren, Alcobra, and Indiana University School of Medicine. He is a past consultant to Alcobra, the Roche Group, and Novartis. He is a current consultant to Fulcrum Therapeutics. He holds equity interest in and is a consultant for Confluence Pharmaceuticals. He is the inventor on intellectual property held by Cincinnati Children’s Hospital Research Foundation and Indiana University describing methods for diagnosis and treatment methods in autism spectrum disorder and fragile X syndrome. RA, PH, APB, and MH have no conflicts to report.
: This study was approved by the Cincinnati Children’s Hospital institutional review board. All procedures performed in this study were in accordance with the ethical standards of the institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Guardians of all participants provided written informed consent prior to participation.